Cellular and Gene Therapy for the Treatment of Hematologic Diseases and Solid Tumors: The Dawn of a New Era
Cellular therapies for the treatment of hematologic diseases have been around for decades but it has become front and center in the last few years with the Food and Drug Administration (FDA) approval of Kymriah (tisagenlecleucel), a CD-19-directed chimeric antigen receptor-T cell (CAR-T cell), for the treatment of acute lymphoblastic leukemia in 2017, the first FDA approved gene therapy in the United States. It was subsequently approved for diffuse large B-cell lymphoma as well. This historic event ushered in a new approach to treat malignancies and other life-threatening diseases.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Yvette Co Tanhehco, Joseph Schwartz Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Hematology | Leukemia | Lymphoma | Science | USA Health